A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(9 sites)

United States

GSK Investigational Site, Canton, Ohio

GSK Investigational Site, Nashville, Tennessee

Canada

GSK Investigational Site, Hamilton, Ontario

GSK Investigational Site, Toronto, Ontario

GSK Investigational Site, Montreal, Quebec

Japan

GSK Investigational Site, Chiba

GSK Investigational Site, Osaka

GSK Investigational Site, Tokyo